Connor, Clark & Lunn Investment Management (CC&L)’s GSK GSK Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$145M	Sell	2,767,591 -49,854	-2%	-$2.64M	0.27%	83
2026 Q1	$155M	Buy	2,817,445 +1,080,327	+62%	+$58.5M	0.36%	62
2025 Q4	$85.2M	Buy	1,737,118 +1,256,734	+262%	+$58.6M	0.22%	95
2025 Q3	$20.7M	Buy	480,384 +382,790	+392%	+$15M	0.07%	260
2025 Q2	$3.75M	Sell	97,594 -132,967	-58%	-$5.08M	0.01%	665
2025 Q1	$8.93M	Buy	230,561 +23,187	+11%	+$849K	0.04%	348
2024 Q4	$7.01M	Sell	207,374 -357,560	-63%	-$12.9M	0.03%	399
2024 Q3	$23.1M	Buy	564,934 +456,319	+420%	+$18.7M	0.11%	147
2024 Q2	$4.18M	Buy	+108,615	New	+$4.57M	0.02%	463
2022 Q4	–	Sell	-845,924	Closed	-$24.9M	–	1302
2022 Q3	$24.9M	Sell	845,924 -59,674	-7%	-$2.26M	0.16%	102
2022 Q2	$49.3M	Buy	+905,598	New	+$50M	0.3%	57
2020 Q3	–	Sell	-646,538	Closed	-$33M	–	1003
2020 Q2	$33M	Buy	646,538 +152,818	+31%	+$7.84M	0.23%	83
2020 Q1	$23.4M	Buy	+493,720	New	+$26.3M	0.21%	91
2018 Q3	–	Sell	-18,800	Closed	-$947K	–	1010
2018 Q2	$947K	Sell	18,800 -263,210	-93%	-$13.3M	0.01%	630
2018 Q1	$13.8M	Sell	282,010 -367,040	-57%	-$17.1M	0.08%	171
2017 Q4	$28.8M	Sell	649,050 -227,506	-26%	-$10.5M	0.17%	110
2017 Q3	$44.5M	Buy	876,556 +175,807	+25%	+$8.92M	0.27%	68
2017 Q2	$37.8M	Buy	700,749 +186,669	+36%	+$9.95M	0.25%	79
2017 Q1	$27.1M	Buy	514,080 +492,000	+2,228%	+$25M	0.18%	100
2016 Q4	$1.06M	Buy	+22,080	New	+$1.09M	0.01%	475
2014 Q3	–	Sell	-16,202	Closed	-$1.15M	–	558
2014 Q2	$1.15M	Hold	16,202	–	–	0.01%	308
2014 Q1	$1.19M	Sell	16,202 -51,950	-76%	-$3.51M	0.01%	355
2013 Q4	$4.83M	Sell	68,152 -2,720	-4%	-$176K	0.04%	159
2013 Q3	$4.57M	Buy	+70,872	New	+$4.56M	0.04%	117

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GSK Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its GSK (GSK) stake by 1.8% in Q2 2026, selling an estimated $2.64M and leaving 2,767,591 shares worth $145M. The position accounts for 0.27% of the portfolio, ranked #83.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GSK in Q3 2013 and has held it in 24 quarters since. The position peaked at $155M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 2,767,591 shares of GSK worth $145M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 49,854 GSK shares in Q2 2026, an estimated $2.64M.
GSK made up 0.27% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #83 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GSK in Q3 2013 and has held it in 24 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s GSK position peaked at $155M in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.